![Abhinav Jain](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Abhinav Jain
Direktor/Vorstandsmitglied bei
AYTU BIOPHARMA, INC.
Vermögen: 121 323 $ am 30.06.2026
Profil
Abhinav Jain is currently an Independent Director at Aytu Biopharma, Inc. since 2023, Talphera, Inc. since 2024, and at both Xtant Medical Holdings, Inc. and Eagle Pharmaceuticals, Inc. starting in 2025.
Formerly, Mr. Jain was an Associate at Angelo, Gordon & Co. LP.
from 2015 to 2017.
Education includes an undergraduate degree from the Massachusetts Institute of Technology in 2012 and an MBA from The Wharton School of the University of Pennsylvania in 2019.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 15.11.2025 | 158’228 ( 0.11% ) | 66 614 $ | 30.06.2026 | |
AYTU BIOPHARMA, INC. 0.18% | 13.10.2025 | 19’500 ( 0.18% ) | 41 925 $ | 30.06.2026 |
TALPHERA, INC. 0.02% | 22.06.2026 | 12’412 ( 0.02% ) | 12 784 $ | 30.06.2026 |
Aktive Positionen von Abhinav Jain
| Unternehmen | Position | Beginn |
|---|---|---|
| AYTU BIOPHARMA, INC. | Direktor/Vorstandsmitglied | 12.06.2023 |
| TALPHERA, INC. | Direktor/Vorstandsmitglied | 22.01.2024 |
| XTANT MEDICAL HOLDINGS, INC. | Direktor/Vorstandsmitglied | 01.08.2025 |
| EAGLE PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 28.08.2025 |
Ehemalige bekannte Positionen von Abhinav Jain
| Unternehmen | Position | Ende |
|---|---|---|
Angelo, Gordon & Co. LP
 Angelo, Gordon & Co. LP Investment ManagersFinance TPG Angelo Gordon seeks alternative investment opportunities that will deliver consistent absolute returns for their clients. The firm manages capital across their Credit and Real Estate strategies, all of which employ a disciplined investment philosophy that combines fundamental in-depth research with a diversification strategy 20 designed to reduce downside risk. The research team is the cornerstone of all investment activities. | Corporate Officer/Principal | 01.01.2017 |
Ausbildung von Abhinav Jain
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
63
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Angelo, Gordon & Co. LP
Angelo, Gordon & Co. LP Investment ManagersFinance TPG Angelo Gordon seeks alternative investment opportunities that will deliver consistent absolute returns for their clients. The firm manages capital across their Credit and Real Estate strategies, all of which employ a disciplined investment philosophy that combines fundamental in-depth research with a diversification strategy 20 designed to reduce downside risk. The research team is the cornerstone of all investment activities. | Finance |
Eagle Pharmaceuticals, Inc.
 Eagle Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercialize injectable products primarily in the metabolic critical care and oncology | Health Technology |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Talphera, Inc.
 Talphera, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceutical products | Health Technology |
The Wharton School of the University of Pennsylvania
 The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aytu Biopharma, Inc.
 Aytu Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Xtant Medical Holdings, Inc.
 Xtant Medical Holdings, Inc. Medical SpecialtiesHealth Technology Manufactures and commercializes surgical products | Health Technology |
